Ovarian cancer

Actionability Pediatric Summary Report

Genes: RAD51C (HGNC:9820) RAD51D (HGNC:9823) BRIP1 (HGNC:20473)
Mode(s) of Inheritance:
Literature Search: 06/04/2025
Curation Status: Released (1.0.0)
Release History
Related Reports
Adult Summary Report: (1.1.1)

Secondary Findings in Pediatric Subjects. Non-diagnostic, excludes newborn screening & prenatal testing/screening.

This topic was prepared by Christine Pak on behalf of Pediatric Actionability Working Group.

The Actionability Summary Report is not available for this topic because there was insufficient evidence for actionability in the early rule out stage.

Actionability Assertions

Gene Condition (MONDO ID) OMIM ID Final Assertion
RAD51C familial ovarian cancer (0016248) 613399 Assertion Pending
RAD51D familial ovarian cancer (0016248) 614291 Assertion Pending
BRIP1 familial ovarian cancer (0016248) 114480 Assertion Pending

Actionability Assertion Rationale

  • This topic was initially scored prior to development of the process for making actionability assertions. The Actionability Working Group decided to defer making an assertion until after the topic could be reviewed through the update process.

Actionability Scores

Outcome / Intervention Pair Severity Likelihood Effectiveness Nature of Intervention Total Score
No scores were found.

Early Rule-Out Summary

This topic did not pass the early rule out stage when reviewed on 06/04/2025 due to insufficient evidence for actionability. Thus, this topic did not move forward for a full evidence curation and summary report. This topic may be reconsidered if additional evidence becomes available.

Findings of Early Rule-Out Assessment

  1. Is there a qualifying resource, such as a practice guideline or systematic review, for the genetic condition?
  2. Does the practice guideline or systematic review indicate that the result is actionable in one or more of the following ways?

    3. a. Patient Management

    b. Surveillance or Screening

    c. Circumstances to Avoid

  3. Is there an intervention that is initiated during childhood (<18 years of age) in an undiagnosed child with the genetic condition?
  4. Does the disease present outside of the neonatal period?
  5. Is this condition an important health problem?
  6. Is there at least on known pathogenic variant with at least moderate penetrance (≥40%) or moderate relative risk (≥2) in any population?